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Abstract 
The outer membrane (OM) in Gram-negative bacteria is an asymmetric bilayer with mostly 
lipopolysaccharide (LPS) molecules in the outer leaflet. During OM biogenesis, new LPS 
molecules are transported from their site of assembly on the inner membrane to the OM by 
seven LPS transport proteins (LptA-G). The complex formed between the integral ß-barrel OM 
protein LptD and the lipoprotein LptE is responsible for transporting LPS from the periplasmic 
side of the OM to its final location on the cell surface. Because of its essential function in many 
Gram-negative bacteria, the LPS transport pathway is an interesting target for the development 
of new antibiotics. A family of macrocyclic peptidomimetics was discovered recently that 
target LptD and inhibit LPS transport specifically in Pseudomonas spp. The related molecule 
Murepavadin is in clinical development for the treatment of life-threatening infections caused 
by P. aeruginosa. To characterize the interaction of these antibiotics with LptD from P. 
aeruginosa, we characterized the binding site by crosslinking to a photolabeling probe. We 
used a hypothesis-free mass spectrometry-based proteomic approach to provide evidence that 
the antibiotic cross-links to the periplasmic segment of LptD, containing a ß-jellyroll domain 
and an N-terminal insert domain characteristic of Pseudomonas spp.  Binding of the antibiotic 
to the periplasmic segment is expected to block LPS transport, consistent with the proposed 
mode of action and observed specificity of these antibiotics. These insights may prove valuable 
for the discovery of new antibiotics targeting the LPS transport pathway in other Gram-
negative bacteria. 
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Introduction 
According to the World Health Organization,1 Gram-negative bacterial infections are causing 
increasing levels of morbidity due to the rise of resistance to established antibiotics,  
particularly in Pseudomonas, Acinetobacter and various Enterobacteriacea species.2 However, 
few new antibiotic classes have been discovered recently to combat Gram-negative bacterial 
infections. A target of special interest in this context is the Gram-negative bacterial outer 
membrane (OM), consisting of an asymmetric bilayer with lipopolysaccharide (LPS) in the 
outer leaflet and membrane phospholipids in the inner leaflet.3 During OM biogenesis, the 
glycolipid LPS molecules are assembled in the cytoplasm and at the inner membrane (IM),4 
before being transported across the periplasm and integrated into the outer leaflet by seven 
essential LPS transport proteins (LptA–LptG), which assemble into a complex spanning the 
entire envelope (Figure 1A).5 At the IM, the LptFGB2 complex extracts LPS molecules from 
the IM, before transport to the OM across a bridge formed by multiple copies of LptA.6,7 The 
LptA bridge thus connects the IM and OM, and provides a pathway for shuttling LPS molecules 
to a complex in the OM comprising the integral ß-barrel membrane protein LptD and the 
lipoprotein LptE.8 In the final step, the LptD/E complex translocates LPS from the periplasmic 
side of the OM into the outer leaflet and the cell surface.9 
 According to the PEZ-model of LPS transport,5,10 ATP hydrolysis catalyzed by the 
LptFGB2 complex, first drives extraction of LPS from the inner membrane and then pumps 
LPS across the LptA bridge and onto the cell surface. The lipid chains of LPS remain anchored 
in V-shaped hydrophobic cavities within the jellyroll domain of first LptC, then LptA,11 and 
finally the jellyroll domain within the N-terminal periplasmic segment of LptD (Figure 1A).8 
The C-terminal domain of LptD, comprising a 26-stranded ß-barrel, is integrated in the OM, 
with the lipoprotein LptE bound within the lumen of the ß-barrel.12-14 One side of the LptD ß-
barrel may transiently accommodate the LPS sugar chain as it reorients vertically on its way to 
the cell surface.15 The lipid A portion of LPS is thought to emerge into the outer leaflet through 
a transient opening in the side of the LptD ß-barrel.10 Several crystal structures of recombinant 
LptD/E from different Gram-negative bacteria have been reported recently.16 However, the 
complex is clearly a highly dynamic machine that shuttles through many different 
conformational states during OM biogenesis. 
 Due to its essential role in OM biogenesis, and exposed location on the cell surface, 
LptD/E has become an interesting target in antibiotic discovery. Amongst the growing interest 
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in naturally occurring host defense peptides and peptidomimetic antibiotics,17,18 a family of 
synthetic macrocyclic ß-hairpin antibiotics including L27-11 (Figure 1B) was described 
recently, which target LptD/E and inhibit LPS transport in Pseudomonas spp.19-22 Photochemical 
cross-linking studies showed that the antibiotics bind with high selectivity to LptD in the OM 
of P. aeruginosa (Pa).19 An important insight into the mode of action came with the isolation 
of spontaneously resistant Pa strains containing a mutation (a six-residue tandem duplication) 
in the periplasmic ß-jellyroll domain of LptD. This mutation confers resistance and blocks 
binding of the antibiotic to LptD.19 However, understanding the mode of action and specificity 
towards Pseudomonas spp. requires a more detailed analysis of the antibiotic binding site. In 
this work, we set out to identify the domain of LptD that mediates binding to L27-11, through 
analysis of site(s) of photo-crosslinking to a related photoprobe called PAL6. Understanding 
how these peptidomimetics interact with pseudomonas LptD/E could aid the discovery of new 
antibiotics targeting LptD in other Gram-negative bacteria. Already a closely related clinical 
candidate called Murepavadin (also called POL7080) has been developed by Polyphor AG as 
a pseudomonas-specific antibiotic.23 Murepavadin recently completed successfully phase-II 
clinical tests in hospital patients with life-threatening pseudomonas lung infections (clinical 
trials identifier NCT02096328). 
 
Results and discussion 
Production and characterization of Pa LptD/EHis  
Pa LptD/EHis was produced in E. coli (Ec) using established procedures, by introducing genes 
for full-length LptD and a His-tagged LptE into an E. coli host (Figure 2A).12-14,24,25 The Pa 
LptD/EHis complex could be isolated by Ni-affinity chromatography, which provides strong 
prima facie evidence for formation of a natively folded ß-barrel domain in Pa LptD, able to 
form a stable complex with Pa LptE. SDS-PAGE of the purified complex, after heat 
denaturation to dissociate LptD from LptE, and in the presence of reducing agent (DTT), shows 
two Coomassie-stained bands at the expected masses (Figure 2B). To investigate the redox 
status of disulfide bonds, the mobility of heat-denatured protein in polyacrylamide gels was 
examined further. 
 Ec LptD (residues 25–784; signal peptide 1–24) can form two disulfides between four 
non-consecutive cysteine residues (Figure 2A), and at least one disulfide must be present in 
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order for LptD to function in LPS transport.26 After heat denaturation by boiling to dissociate 
the complex, the mobility of LptD in gels changes in a manner characteristic of the oxidation 
state of these disulfide bonds linking the jellyroll domain to the ß-barrel domain.26,27 Reduced 
and denatured Ec LptD (LptDRED) migrates faster at ≈90 kDa, whereas non-reduced LptD 
containing at least one interdomain disulfide (LptDOX) linking the periplasmic segment to the ß-
barrel, migrates more slowly at ≈110 kDa.24 Pa LptD is larger (34–924 residues, ≈100 kDa) and 
contains six cysteines, including four that are likely to form disulfides analogous to those seen 
in Ec LptD (see below and Figure 2A). The periplasmic segment of Pa LptD (res. 34–323) 
comprises not only a jellyroll domain, similar to that present in Ec LptD, but also an additional 
≈100 residue domain found in LptD from pseudomonads, and in very few other Gram-negative 
bacteria. This insert domain also contains a pair of cysteine residues that might form a disulfide, 
as indicated in Figure 2A. 
 The mobility of heat denatured Pa LptD in SDS-PAGE was analyzed with and without 
reduction with DTT. Both the recombinant Pa LptD/EHis extracted from Ec and wild-type Pa 
LptD/E extracted from Pa PAO1 membranes, behaved similarly on SDS-PAGE (Figure 2C), 
with the denatured and non-reduced LptD migrating with apparent size ≈130 kDa and the 
reduced form (with DTT) with apparent size ≈100 kDa. These results suggest that putative 
interdomain disulfides are present both in vivo and in vitro, linking the ß-barrel to the 
periplasmic segment in Pa LptD/EHis. Further support for this conclusion came by examining 
the gel mobility of targeted Cys-to-Ser mutants of the Pa LptD/EHis produced in E. coli, in 
analogy to similar experiments reported earlier for the Ec LptD.26 A mutant Pa LptD with all 
six cysteine residues mutated to serine (Pa LptDSSSSSS; where SSSSSS signifies the sequential 
replacement of all six Cys to Ser) could also be purified by Ni-affinity chromatography, and 
upon heating migrated under both reducing and non-reducing conditions in an SDS-PAGE gel 
at the position found for LptDRED (≈100 kDa) (Figure 2D). This result parallels that reported for 
the Ec LptD, where eliminating all Cys residues does not significantly destabilize LptD or 
prevent formation of the LptD/E complex.26 When two cysteine residues expected to form 
interdomain disulfides, analogous to those in Ec LptD (Figure 2A), are re-introduced 
(C270/C859 (LptDSSSCSC) and C39/C858 (LptDCSSCS)) each protein after heating under non-reducing 
conditions migrated either partly (LptDSSSCSC) or fully (LptDCSSCS) at ≈130 kDa, whereas the reduced 
form migrated at ≈100 kDa (Figure 2D). In some assays Pa LptD (wt and mutant) showed both 
130/100 kDa bands when analyzed under non-reducing conditions (Figure 2D), possibly due 
to partial reduction of the protein during the cell disruption procedure or incomplete oxidation 
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in E. coli.  These results indicate that disulfides homologous to those seen in Ec LptD can form 
in the Pa LptD, and that this gel mobility shift assay provides a useful method to monitor the 
interdomain redox status of the Pa LptD/E complex.26 In summary, these results suggest that 
the recombinant Pa LptD/EHis has a native-like fold, like that of LptD/E present in Pa 
membranes. 
 
Binding of antibiotic to Pa LptD/EHis 
Binding of antibiotic L27-11 to recombinant Pa LptD/EHis was tested using two different 
biophysical methods, surface plasmon resonance (SPR, GE Healthcare) and microscale 
thermophoresis (MST, Nanotemper Technologies). For SPR studies, the protein was 
immobilized through a Ni-NTA ligand, covalently linked to the biosensor surface, and 
increasing concentrations of free L27-11 were eluted over this surface. Association and 
dissociation kinetics fast on the SPR timescale were observed (Figure 3A), so equilibrium 
responses were analyzed with a Langmuir binding model, which gave an apparent KD of 32 ± 
10 nM for the interaction. A binding isotherm could also be detected by MST with both 
components now free in solution (Figure 3B), using the fluorescently labeled derivative fl-L27-
11 (Figure 4). Titrating fl-L27-11 with LptD/EHis gave a low but reproducible response, and an 
apparent KD ≈ 13 ± 5 nM for the interaction. The enantiomer of L27-11 (ent-L27-11) shows no 
antimicrobial activity against Pa.19 As a control, therefore, binding of ent-L27-11 was 
monitored to fluorescently labeled LptD/EHis by MST. However, a binding isotherm could only 
be detected at peptide concentrations ≈1000x higher than seen for L27-11. We conclude that 
the recombinant Pa LptD/EHis complex retains an ability to bind enantioselectively the 
peptidomimetic antibiotic in vitro, in a concentration range similar to the observed 
antimicrobial activity of L27-11,19 although the MIC reflects inhibition of growth and not a 
binding reaction. 
 
Trypsin digestion of Pa LptD/EHis 
Folded ß-barrel proteins are often thermally stable and resistant to trypsin digestion. The 
reported trypsin digestion of Ec LptD leads to release of a ≈62 kDa trypsin resistant fragment 
starting at F203, close to the start of the C-terminal ß-barrel domain (Figure 2A).24 When the 
Pa LptD/EHis was partially digested with trypsin, two fragments could be readily detected by 
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SDS-PAGE, one at ≈95 kDa (fragment F1) and another at ≈70 kDa (fragment F2) (Figure 5A). 
N-terminal Edman sequencing revealed that fragment F1 arises by trypsin cleavage at R107, 
whereas fragment F2 arises by cleavage at R301. Only the F1 fragment is recognized in 
Western blotting by polyclonal anti-LptD antiserum raised against the C-terminal 20 residues, 
likely due to loss through proteolysis in F2 of the C-terminal segment including the antibody 
epitope. This C-terminal segment (res. 895–924) follows the last ß-strand and so is not an 
integral part of the ß-barrel. R107 lies within the predicted insert domain (Figure 2A), whereas 
R301 lies close to the start of the ß-barrel domain. 
 
Photolabeling experiments  
For photolabeling experiments, the probe PAL6 was developed (Figure 4). Compared to L27-
11, PAL6 contains multiple substitutions of Arg/Lys residues (Figure 1B) for diaminobutyric 
acid (Dab), with the result that the macrocyclic peptide is much more stable to proteolysis by 
trypsin.19,21 PAL6 retains, however, potent antimicrobial activity (MIC against Pa PAO1 ≈ 0.03 
µg/mL in MH-II broth). 
 In vivo photolabeling of whole Pa cells by PAL6 showed highly selective labeling of 
LptD by Western blotting (Figure 5B). Upon trypsin digestion of Pa LptD/E extracted from 
Pa membranes, the formation of the F1 fragment (≈95 kDa) was detected in a Coomassie-
stained gel, and was confirmed by in-gel trypsin digestion and tandem mass spectrometry 
(MS/MS) analysis of fragments, as well as by reaction with anti-LptD antibodies recognizing 
the C-terminal 20 residues (Figure 5B/C). Importantly, however, the F1 fragment gave no 
signal upon biotin detection, showing that the F1 fragment has lost the biotin tag, and therefore 
the site of photo-crosslinking. 
 In vitro photolabeling of Pa LptD/EHis by PAL6 also showed highly selective labeling 
of LptD by Western blotting (Figure 5D/E). Upon trypsin digestion, the formation of the F1 
fragment (≈95 kDa) was detected in a Coomassie-stained gel, and was confirmed by in-gel 
trypsin digestion and tandem mass spectrometry (MS/MS) analysis of fragments, as well as by 
reaction with anti-LptD antibodies recognizing the C-terminal 20 residues. However, the F1 
fragment now retains a strong signal upon biotin detection (Figure 5C/D), showing that this 
fragment contains covalently attached photoprobe. However, no biotin signal was detected in 
the F2 fragment, suggesting that the ß-barrel is not labeled by the photoprobe. Attempts to 
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directly detect smaller biotinylated peptides using this Western blotting approach gave 
inconclusive results. A more detailed analysis was therefore undertaken using a mass 
spectrometry-based approach. 
 
Detection of photolabeled fragments by mass spectrometry  
The photolabeling by PAL6 of recombinant Pa LptD/EHis was analyzed by quantitative MS-
based proteomics, which starts with the assumption that photo-crosslinking of PAL6 to 
LptD/EHis results in covalent attachment of the photoprobe to one or more spatially proximal 
amino acids, in or close to the antibiotic binding site. Compared to unlabeled protein, PAL6 
labeled peptides obtained upon proteolytic digestion are then less likely to be detected by MS, 
due to altered peptide precursor mass, fragmentation patterns and ionization efficiency. Thus, 
comparing peptide abundances between PAL6-labeled and unlabeled LptD/EHis digests, permits 
the identification of PAL6 modified regions in a hypothesis-free fashion. 
 Comprehensive detection of LptD and LptEHis peptides across structural domains by MS 
is a prerequisite for the unbiased identification of PAL6 binding sites. Thus, we first optimized 
proteolytic digestion and MS detection of LptD/EHis-derived peptides. For this, equal amount of 
PAL6-labeled and unlabeled LptD/EHis protein was reduced and sequentially digested under 
denaturing conditions with a mix of proteolytic enzymes consisting of Lys-C, trypsin and 
chymotrypsin. A small aliquot of each sample was pooled and analyzed by HPLC-MS/MS in 
data-dependent acquisition (DDA) mode for sensitive and discovery-driven identification of 
proteolytic peptides. A peptide search using a database containing pseudomonas LptD/E 
protein sequences led to identification of 409 and 80 peptides (false discovery rate (FDR) < 
0.01), representing a sequence coverage of 85% and 81% for LptD and LptEHis, respectively 
(Table S2 and Figure S4).  Although, folded ß-barrel proteins are often resistant to trypsin 
digestion, the identified proteolytic peptides of LptD originate from its insert, jellyroll as well 
as ß-barrel domain. This indicates comprehensive and structure independent coverage of 
LptD/EHis by MS under optimized conditions.  
 To identify potential PAL6 binding sites, MS detectable peptides were analyzed for an 
altered abundance upon PAL6 photo-crosslinking. For this, PAL6-photolabeled and unlabeled 
LptD/EHis protein digests were analyzed by HPLC-MS/MS in data-independent acquisition 
(DIA) mode for label-free quantification of LptD/EHis derived peptides. Peptides were quantified 
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by integration of associated fragment-ion traces. Data analysis using Spectronaut software 
(Biognosys, Schlieren) allowed relative quantification of 335 peptides with unique amino acid 
sequences, 280 of which could be assigned to LptD and 55 to LptEHis (Table S2). Thirty-six 
peptides were significantly down-regulated upon PAL6 photo-crosslinking (fold change of > 
1.5 and q-value < 0.05) and all of them stem from LptD (Figure 6). A cluster including most 
significantly regulated peptides maps to the b-jellyroll region of LptD and shares the unique 
amino acid sequence “ENR” (res. 199–201). Additionally, a second population of peptides 
significantly affected by PAL6 photo-crosslinking maps to the insert domain of LptD and 
comprises the sequence stretch “ETV” (res. 85–87). From this we conclude that PAL6 
preferentially binds to the periplasmic region of recombinant LptD/EHis in vitro, and more 
specifically, to defined segments within the b-jellyroll and the pseudomonas-specific insert 
domain of LptD. 
 
Discussion 
 The peptidomimetic L27-11 (Figure 1) is a potent antibiotic acting specifically against 
Pseudomonas spp., and a related photoprobe was shown earlier to photolabel LptD with high 
selectivity in whole cells of P. aeruginosa (Pa).19 In this work, in vivo photolabeling of Pa 
PAO1 with the photoprobe PAL6 also leads to highly selective labeling of LptD (Figure 5B). 
However, the low natural abundance of LptD in Pa and the poor efficiency of photochemical 
cross-linking with this photoprobe, are major obstacles in efforts to analyze the site(s) of in 
vivo photolabeling in this large membrane protein. Furthermore, the carbene photochemically-
generated from PAL6 can also undergo fast internal quenching by 1,2-H-shift, which lowers 
significantly the cross-linking efficiency. Before discussing the sites of photo-crosslinking by 
PAL6, we first discuss in more detail the known structures of LptD from various Gram-
negative bacteria and the likely domain organization of Pa LptD. 
 As indicated in Figure 2, Ec LptD comprises a C-terminal ß-barrel domain and an N-
terminal periplasmic domain of ≈200 residues (see also Figure 1C). The Ec LptD contains four 
Cys residues that form two disulfide bonds linking the barrel domain with the jellyroll domain, 
which are required for the proper function of the transporter.24,26,27 Crystal structures are available 
of full-length LptD/E from Shigella flexneri (PDB 4Q35) (shown in Figure 1C), which has 
very high sequence identity to the Ec LptD, as well as Klebsiella pneumoniae (5IV9).13,14 Both 
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structures include the LptD transmembrane ß-barrel and the complete N-terminal periplasmic 
segment with its ß-jellyroll domain. In addition, structures of truncated forms of LptD, lacking 
the entire N-terminal periplasmic segment are available for LptD/E from Salmonella enterica 
(4N4R),12 P. aeruginosa (5IVA),14 Escherichia coli (4RHB) (to be published), Klebsiella 
pneumoniae (5IV8)14 and Yersina pestis (5IXM).14 In all these crystal structures, the 26-stranded 
LptD ß-barrel domain is highly conserved and the lumen of the barrel is plugged in each case 
by LptE. However, the crystal structure of full-length Pa LptD/E with the periplasmic domain 
has not yet been reported. In Pseudomonas spp., the periplasmic segment of LptD is 
significantly longer than that in most other g-proteobacteria, due to the presence of an 
additional N-terminal ≈100 residue "insert" domain of unknown structure and function (res. 
45–144) (Figure 2A). The Pa ß-jellyroll domain is similar in sequence (similarity 47%; identity 
28%) to that in Shigella flexneri LptD (Table S1), suggesting a similar ß-jellyroll fold (res. 
145-323). Based upon a sequence alignment, a homology model for the jellyroll in Pa LptD 
could be generated (see Supporting Information). The relative orientation of the ß-jellyroll and 
b-barrel domain in Pa LptD could be very similar to that in the full-length Sf LptD crystal 
structure. In particular, the sequences of the region linking the ß-jellyroll to the barrel in Pa 
LptD (I317–L326) and Shigella flexneri (V220–L229) contain conserved residues, indicating 
a similar fold in this region. For the insert domain, a sequence motif search in the PDB database 
revealed low sequence similarities with parts of a human VH Ig-like domain (PDB 1T2J). Ig-
like domains are frequently found in E. coli cell surface proteins, where they play various roles 
in host cell adhesion and invasion by pathogenic strains.28 A homology model of the Pa insert 
domain with a truncated Ig-like fold could also be generated (see Supporting Information).28 
However, this model is speculative, and it is currently unclear how the individual domains 
within the periplasmic segment (insert, ß-jellyroll and ß-barrel) are arranged in 3D space. As 
discussed below, the photolabeling experiments provide clear evidence that the antibiotic binds 
to the periplasmic portion of LptD, but without structural information it is not yet possible to 
analyze the likely binding site in terms of 3D structures (vide infra). 
 The first information about possible sites of in vivo photo-crosslinking of PAL6 to Pa 
LptD could be obtained by exploiting highly sensitive biotin detection in Western blotting of 
trypsin fragments derived from photolabeled LptD (Figure 5B/C). Crosslinking of PAL6 
occurs to a segment of the periplasmic insert domain (res. 34-107) that is cleaved from the F1 
fragment by trypsin. No evidence was obtained for labeling of the ß-barrel domain in LptD. 
For analysis of in vitro photo-crosslinking, a quantitative mass spectrometry-based proteomics 
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approach could be used, which identifies differences in abundance of proteolytic peptide 
fragments derived from labeled versus unlabeled LptD. This approach avoids problems that 
arise when attempting to directly and comprehensively detect labeled protein fragments by MS, 
due to uncertain mass shifts and ion-suppression effects that occur with modified peptide 
fragments. Rather, a hypothesis-free approach was taken here to map in one experiment all 
fragments of the protein that are modified by the photoprobe. The results obtained illustrate the 
potential of the approach as a method for mapping ligand-receptor binding sites. The MS 
results show that cross-linking occurs in vitro to two sites in LptD, one around res. 85–87 
(ETV) in the insert domain, and another within the ß-jellyroll domain around residues 199–
201 (ENR) (Figure 6).  
 Whereas in vitro labeling around res. 85-87 in the insert domain is consistent with the 
observations made for in vivo labeling, the second site of in vitro cross-linking around res. 199-
201 was not detected in the in vivo photolabeling experiments. We conclude, therefore, that 
although a native-like fold exists in vitro, there must be some differences between the antibiotic 
binding site in LptD detected by photolabeling in vitro and in vivo. We hypothesize that this 
may be due to the different environments experienced by the LptD/E complex. For example, 
in vivo the protein is integrated into a membrane bilayer and may be shuttling between different 
conformational states during LPS transport, whereas in vitro the LptD/EHis complex is 
solubilized in a detergent micelle. Recent studies, for example, have shown for one ß-barrel 
protein (OmpX) that while it forms a stable ß-barrel in detergent micelles, bicelles and 
nanodiscs, the dynamics of the protein differ substantially between the detergent and lipid 
environments.29 Furthermore, in vivo the N-terminal region of LptD, where binding to the 
antibiotic should occur, is bound to LptA as part of the Lpt transport macromolecular complex. 
The absence of LptA in vitro may also affect the structure or dynamics of this region in LptD. 
Changes in conformation and/or dynamics of LptD might have a significant effect on the 
diffusion and site of eventual cross-linking of the reactive carbene generated by photolysis of 
PAL6. Notwithstanding this, we believe that the results presented are important, because they 
show for the first time that the ß-barrel domain is not labeled, and that both in vivo and in vitro 
photolabeling provide evidence for a binding site within the periplasmic segment of LptD. 
 As mentioned earlier, one additional evidence that the antibiotic binding site is close to 
the ß-jellyroll domain came from the isolation of a resistant mutant of Pa, containing a six-
residue tandem duplication at res. 210–215 in LptD.19 This mutation blocks binding of the 
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antibiotic to LptD, and maps in a homology model of the jellyroll domain to the tip of a ß-
hairpin loop on one side of the V-shaped hydrophobic groove (Figure 7B). Interestingly, on 
the opposite side of the V-shaped groove in this model lies a hairpin loop containing one of the 
sites detected by photo-crosslinking (res. 199-201). It is noteworthy that the three sites 
implicated in antibiotic binding are discontinuous in the primary sequence of the protein (res. 
85-87; res. 199-201; res. 210-215), yet folding may bring them close together in the three-
dimensional structure of the protein. Multiple attempts were also made here to express the 
periplasmic segment of Pa LptD as a recombinant protein, to facilitate structural studies. 
However, 15N-labeling of the protein and analysis of amide proton dispersion in 15N-1H 2D-
HSQC NMR spectra showed that the recombinant protein could not be obtained in a stable 
folded form (results not presented).30 Finally, the unique selectivity and mode of action of the 
antibiotic for pseudomonads can now be understood in terms of the direct involvement of the 
LptD periplasmic insert domain in antibiotic binding, and this insert domain is found almost 
exclusively in the LptD of pseudomonads. The current model for LPS transport proposes that 
the lipid chains of LPS interact with the hydrophobic groove of the jellyroll domains in LptA 
and LptD. A molecule that binds in or close to this groove in LptD should therefore be able to 
interrupt LPS transport, consistent with the proposed mechanism of action.20 Further progress 
on this challenging problem will likely require a 3D structure of the periplasmic segment of Pa 
LptD and its complex with bound antibiotic. 
 
METHODS 
Production of Pa LptD/E in E. coli. The lptD and lptE genes from P. aeruginosa (Pa) PAO1 
(PA0595 and PA3988) were amplified by PCR from genomic DNA (see Supporting 
Information for primer sequences). Pa lptD was cloned into NdeI/BamH1 restriction sites in 
pET3a (Novagen) including its native signal sequence. Upon expression in E. coli and cleavage 
of the signal peptide, LptD has the native N-terminus (res. 34–924) (Figure 2A). Pa lptE was 
cloned into NcoI/XhoI sites in the pCDFduet-1 vector (Novagen) with its native signal sequence. 
Upon expression in E. coli, addition of diacylglycerol to the conserved C20 residue, signal 
peptide cleavage and N-acylation by the Lnt transacylase,31 Pa LptE is produced with an N-
terminal lipid anchor and a C-terminal His6 tag (LptEHis). Both plasmids were introduced into E. 
coli BL21 DE3 and simultaneous expression of Pa LptD and LptEHis was initiated by addition 
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of IPTG (100 µM) at OD600 = 0.6. After cell growth for 16 h at 23°C, an OM preparation was 
isolated by differential ultracentrifugation and a washing step using 0.5% N-lauroylsarcosine.32 
 The OM pellet was dissolved in PBS (50 mM, pH 7.4) containing 1% (w/v) LDAO and 
lysozyme (100 µg mL-1), and the Pa LptD/EHis complex was purified by Ni-affinity 
chromatography, with elution in buffer containing 300 mM imidazole and 1% n-octyl-ß-D-
glucopyranoside (OG). Fractions containing Pa LptD/EHis were concentrated (50 kDa cut-off 
filter) and purified by gel filtration on Superdex 200 (PBS buffer with w/v 1% OG). The 
resulting Pa LptD/EHis complex shows mainly two bands with the expected apparent masses on 
Coomassie-stained SDS-PAGE (Figure 2B). An N-terminal amino acid analysis and in-gel 
trypsin digestion with MS/MS analysis confirmed the identity of the ≈105 kDa band as Pa 
LptD, whereas direct MS confirmed the ≈25 kDa band as Pa LptEHis. Western blotting showed 
that each protein reacted with complementary IgG antiserum raised against a peptide 
corresponding to the C-terminal 20 amino acids of LptD (anti-LptD) or the C-terminal 16 
residues of Pa LptE. The anti-sera do not recognize the corresponding E. coli LptD/E upon 
Western blotting (not shown). Individual site-specific mutants were generated using 
QuikChange multi-site directed mutagenesis kit (Agilent) and produced using the method 
above. 
Trypsin digestion. LptD/EHis (100 µg) and sequencing grade trypsin were incubated in PBS 
buffer with 1% OG at 37oC. Aliquots were removed at time intervals, boiled with SDS-loading 
buffer, and analyzed by SDS-PAGE (8% gel). The gel was either stained with Coomassie blue, 
or used for Western blotting (PVDF membrane) for anti-LptD or biotin detection (Figure 5). 
Binding studies. For SPR studies a NiHC1000 sensor chip with a BIAcore T100 (GE 
Healthcare) instrument was equilibrated with PBS buffer (pH 7.4, 50 mM) containing 1% w/v 
OG and loaded with Pa LptD/EHis (160 nM) to a surface density of ca. 3500 RU. After blocking 
free Ni-sites with poly-His-tagged peptide, a series of analyte (L27-11) concentrations at 0.25–
500 nM, in the same buffer, at a flow rate of 20 µL mL-1, were eluted over the biosensor surface 
at 25°C for 60 s, followed by dissociation without analyte over 180 s. The biosensor surface 
was regenerated with 100 mM EDTA for 600 s between each run. The entire experiment was 
repeated in triplicate. For data analysis, a double referencing approach was used with BIAcore 
T100 evaluation software v. 1.1.1. The steady state response was used to determine a KD of 32 
± 10 nM (Figure 3A). 
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 Microscale thermophoresis (MST) experiments were performed with a Monolith 
NT.115 instrument (NanoTemper Technologies) with hydrophobic capillaries at room 
temperature. A dilution series of LptD/EHis (5000–0.15 nM) was added to fl-L27-11 (Figure 4) 
at 10 nM in PBS buffer (pH 7.4, 50 mM) containing 1% w/v OG. Binding isotherms were 
generated using NTAffinityAnalysis v2.0.1334 software provided by the manufacturer (Figure 
3B). The average KD from triplicate measurements was 13 ± 5 nM. In addition, binding of L27-
11 and ent-L27-11 were measured under the same conditions using LptD/EHis labelled using a 
DylightTM 650-N-hydroxysuccinimide ester labelling kit (Thermofisher). 
Photolabeling experiments. The photoprobe PAL6 (Figure 4) was used for both in vivo and 
in vitro labeling of purified Pa LptD/EHis complex and methods reported earlier.19 After 
photolabeling, the complex was digested with trypsin, and then analyzed by SDS-PAGE (8% 
gel) with Western blotting using anti-LptD antibodies, or with detection of biotinylated 
(photolabeled) proteins by chemiluminescence detection using a streptavidin-HRP conjugate 
(Figure 5). 
MS Analyses. Labeled and unlabeled Pa LptD/EHis (9 µg) were reconstituted in detergent free 
3 M urea in 50 mM ammonium bicarbonate (AmBic) and reduced for 30 min at 37°C with 5 
mM TCEP. Each solution was split into three aliquots and proteolytically digested with 0.2 µg 
lysyl endopeptidase (Lys-C) (Wako Pure Chemical Industries) for 14 h at 37°C. Samples were 
diluted to 1.5 M urea with 50 mM AmBic and further digested for 6 h at 37°C with 0.3 µg 
sequencing grade modified trypsin (Promega Corporation). After dilution to 0.75 M urea with 
50 mM AmBic, 0.5 µg chymotrypsin was added for 16 h at 37°C. Samples were acidified to 
pH < 3 by the addition of formic acid and subjected to C18 purification using 3–30 µg 
UltraMicroSpin Columns (The Nest Group) according to manufacturer's instructions. HRM 
calibration peptides (Biognosys AG) were added to the samples prior to mass spectrometric 
analysis. 
 Peptide samples were separated by reversed-phase HPLC, using a column (75 µm inner 
diameter, New Objective) that was packed in-house with a 15-cm stationary phase (ReproSil-
Pur C18-AQ, 1.9 micrometer) and connected to a nano-flow HPLC combined with an 
autosampler (EASY-nLC II, Proxeon). The HPLC was coupled to a Q-Exactive plus mass 
spectrometer (Thermo Scientific) equipped with a nano electrospray ion source (Thermo 
Scientific). Peptides were loaded onto the column with 100% buffer A (99.9% H2O, 0.1% 
formic acid (FA)) and eluted for MS detection at a constant flow rate of 300 nL/min with a 70-
 15 
min linear gradient from 6–28% buffer B (99.9% MeCN, 0.1% FA) and 4 min 28–50% B. 
After the gradient, the column was washed 4 min with 98% buffer B. In between runs, the 
column was cleaned for 18 min with two steep consecutive gradients of MeCN (10–98%). 
Electrospray voltage was set to 1.8 kV, sheath and auxiliary gas flow to zero and capillary 
temperature to 250°C.  
 Samples were first subjected to MS analysis in data-dependent acquisition (DDA) mode 
for comprehensive and discovery-driven detection of proteolysis derived LptD/EHis peptides. In 
DDA mode, the mass spectrometer automatically switched between MS and MS/MS detection. 
Following a high-resolution survey mass scan (from 300 to 1,700 m/z) acquired in the Orbitrap 
with resolution R = 70,000 at 200 m/z (automatic gain control target value 1*106), the 15 most 
abundant peptide ions with a minimum intensity of 420 were selected for subsequent HCD 
fragmentation with an isolation window of 1.5 Da and fragments were detected by MS/MS 
acquisition at resolution R = 35,000 (automatic gain control target value 5*104). Target ions 
already selected for fragmentation were dynamically excluded for 30 s. Next, samples were 
analyzed by MS in data-independent acquisition (DIA) mode for the sensitive relative 
quantification of LptD/EHis peptides between PAL6 labeled and unlabeled condition. Each DIA 
cycle consists of one full mass scan from 400 to 1220 m/z at resolution R = 35,000 (automatic 
gain control target value 5*106) followed by 19 sequential DIA MS/MS scans with isolation 
windows varying between 24 and 220 Da and resolution R = 35,000 (automatic gain control 
target value 3*106).  
 Fragment ion spectra acquired in DDA mode were matched against a protein database 
containing LptD and LptE amino acid sequences in an iterative SEQUEST HT search using 
Proteome Discoverer v.2.1 (Thermo Scientific). First iteration assumed peptides to be fully 
digested by trypsin with a maximum of 2 missed cleavage sites, followed by searching for fully 
chymotrypsin cleaved peptides with a maximum of 2 missed cleavages and semi-tryptic ones 
with a maximum of 2 missed cleavage sites. For all iterations, the precursor and fragment mass 
tolerance was set to 20 ppm and 0.02 Da, respectively, and methionine oxidation was set as 
dynamic modification. Identified peptide spectrum matches were filtered for FDR < 1% and 
exported as spectral library together with common contaminants and standards using 
Spectronaut v9.0 (Biognosys AG) (see Supporting Information). Raw files of mass 
spectrometry analysis in DIA mode were loaded into Spectronaut. Peptides were identified 
using above generated spectral library and quantified based on chromatographic traces of 
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corresponding fragment ions (Table S2). Differential abundance testing was performed at 
stripped peptide sequence level. LptD/E peptides with an abundance fold change of at least 1.5 
and an adjusted p-value (q-value) of < 0.05 were considered to be crosslinked with PAL6 
(Figure 6). Obtained peptide variants were mapped to parental LptD/E sequences using Protter 
proteoform visualization tool33 and Clustal Omega multiple sequence alignment software to 
identify preferential binding sites of PAL6 to LptD/EHis (Figure S4). Mass spectrometric data 
were deposited to the ProteomeXchange Consortium (http://www.proteomexchange.org/) via 
the PRIDE partner repository (data set identifier: PXD008577). 
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Figure legends 
Figure 1. The structure and function of a peptidomimetic antibiotic. A, Schematic 
representation of the LPS transport pathway from the bacterial IM to the OM mediated by 
LptA–G (see text). Structures from PDB files were used for LptA (2R1A) and LptD/E (4Q35). 
B, Structure of the peptidomimetic antibiotic L27-11. C, Ribbon representation of the X-ray 
structure of the LptD/E complex from Shigella flexneri (PDB 4Q35). 
 
 
Figure 2. Domain organization and characterization of Pa LptD/EHis. A, Comparison of 
domain organization in LptD from Pa (res. 34-924; signal peptide (SP) res. 1-33) and E. coli 
(res. 25-784), and Pa LptEHis. Known Cys-Cys disulfide links in Ec LptD are shown in orange 
(see text). Putative disulfides in Pa LptD are shown with dotted lines. The pseudomonas-
specific insert domain (predicted res. 45-144) is indicated in orange. B, SDS-PAGE of purified 
Pa LptD/EHis after heat denaturation and reduction with DTT (positions of LptD and LptEHis are 
indicated). C, Western blot showing the mobility in SDS-PAGE after heat denaturation; of Pa 
LptD extracted from P. aeruginosa PAO1 membranes (lanes 1), compared to that of LptD/EHis 
isolated from E. coli (lanes 2), either with or without reduction by DTT. Detection is with anti-
LptD antibodies. D, Analysis of Pa LptD (wt, from P. aeruginosa) and Cys-to-Ser mutants of 
LptD/EHis by Western blotting with anti-LptD antibodies. 
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Figure 3. Binding of antibiotic to LptD/EHis. Two independent biophysical methods were used 
for binding studies; A, SPR measurements of L27-11 binding to Pa LptD/EHis immobilized on 
a NiHC1000 biosensor surface (BIAcore T100). Responses are shown for increasing 
concentrations of L27-11 (0.25–500 nM) in the flow buffer. A standard Langmuir binding 
model was used to determine KD (32 ± 10 nM) from triplicate measurements. B, Binding curves 
from microscale thermophoresis measurements in buffer (see experimental section) with a 
constant amount of fl-L27-11 and varying concentrations of Pa LptD/EHis. Three independent 
experiments are shown (KD of 13 ± 5 nM). 
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Figure 4. Structures of probes. Structures of the photoprobe PAL6 and the fluorescent probe 
(fl-L27-11) used for MST binding studies. 
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Figure 5.  Photolabeling of Pa LptD/EHis. A, Partial trypsin digestion of Pa LptD/EHis (ratio in 
µg of LptD/E:trypsin shown). LptD after heating and reduction with DTT (≈100 kDa), and 
trypsin fragments F1 (≈95 kDa) and F2 (70 kDa) are indicated (N-terminal sequences 
determined by the Edman method are shown). B, OM extract of in vivo photolabeled Pa by 
Coomassie-stained SDS-PAGE (8% gel), same after blotting and biotin detection, and after 
anti-LptD detection. With (+) and without (-) trypsin digestion, showing that fragment F1 is 
not biotin-labeled. C, Repeat as in B but showing course of trypsin digestion. Lane-1 shows 
LptD control (Non-labeled, NL). Top, anti-LptD Western blot; bottom, biotin detection. Intact 
LptD and fragment F1 are indicated, and again F1 is not biotin-labeled. D, In vitro photolabeled 
Pa LptD/EHis analyzed by Coomassie-stained SDS-PAGE (8% gel) (left), and after blotting and 
biotin detection (right); both with (+) or without (-) partial trypsin digestion. Fragment F1 is, 
and F2 is not biotin-labeled. E, As in D but showing time course (in min.) of trypsin digestion 
(µg of LptD/E:trypsin ≈ 50:1). Lane-1 shows LptD control (Non-labeled, NL). Top, anti-LptD 
Western blot; bottom, biotin detection. Intact LptD and fragment F1 are indicated. 
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Figure 6. Volcano plot showing depletion of proteolytic peptide fragments from LptD by 
in vitro photolabeling with PAL6. A, Peptide fragments from photolabeled and unlabeled 
LptD were quantified by MS-based proteomics and the fold change calculated. Peptides with 
an abundance change of larger than ±1.5 fold and q-value <0.05 were considered as 
significantly regulated by photolabeling. Regulated peptides derived from the insert domain 
(orange, triangles), ß-jellyroll (purple, squares) and ß-barrel domain (green circles) of 
LptD are depicted. Significantly downregulated peptides of the insert and beta jellyroll domain 
share a unique amino acid sequence ETV (res. 85–87) and ENR (res. 199–201), respectively. 
B, List of the significantly depleted peptide fragments of the LptD insert and ß-jellyroll 
domains (orange and purple) as quantified by MS. The ETV and ENR sequence motifs are 
highlighted in bold. 
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List	of	significantly	downregulated	peptides	identified	by	MS:
LptD domain Sequence LptD	domain Sequence
insert SVSTAAAGSSVSGSGGETVEAEPTQR β-jellyroll DESPTYVSAK
insert AAAGSSVSGSGGETVEAEPTQR β-jellyroll TLAGDVVLR
insert AAGSSVSGSGGETVEAEPTQR β-jellyroll QGSMQVEGDEANLH
insert AGSSVSGSGGETVEAEPTQR β-jellyroll GSMQVEGDEANLHQLENR
insert GSSVSGSGGETVEAEPTQR β-jellyroll QVEGDEANLHQLENR
insert SSVSGSGGETVEAEPTQR β-jellyroll QVEGDEANLHQLENRGELVGNVK
insert SVSGSGGETVEAEPTQR β-jellyroll VEGDEANLHQLENRGELVGNVK
insert VSGSGGETVEAEPTQR β-jellyroll GDEANLHQLENRGELVGNVK
insert SGSGGETVEAEPTQR β-jellyroll DEANLHQLENRGELVGNVK
insert GSGGETVEAEPTQR β-jellyroll QLENRGELVGNVK
insert SGGETVEAEPTQR β-jellyroll ENRGELVGNVK
insert GGETVEAEPTQR β-jellyroll NRGELVGNVK
insert GETVEAEPTQR β-jellyroll GMLVVGDHAQVQ
insert ETVEAEPTQR β-jellyroll RSENAIIM
insert RSADYSHLDWIPREK β-jellyroll RSENAIIMLK
insert SADYSHLDWIPREK β-jellyroll SENAIIMLK
insert SHLDWIPREK β-jellyroll ENAIIMLK
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Figure 7.  Representation of Pa LptD/E. A, Structure of LptD/E, with the LptD N-terminus, 
insert domain and jellyroll domain shown schematically, since no 3D structural information is 
available for the periplasmic segment of Pa LptD (see Figure 1C and 2A). The connectivity of 
the protein suggests that the insert, jellyroll and ß-barrel domains will be in close proximity to 
each other, but their relative orientations are presently unknown. B, A homology model of the 
Pa LptD jellyroll domain is shown, with res. 199–201 (cyan) and the site of mutation conferring 
antibiotic resistance (res. 210–215, yellow) indicated (see text). 
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